Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618412 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EHTTTSHRHSD17B10 | |
| SCHEMBL7913275 | 0.98 | SMN1; SMN2 (0.97) | SMN1; SMN2KDM4EHTTTSHRHSD17B10 | |
| SCHEMBL29375167 | 0.96 | SMN1; SMN2 (0.93) | SMN1; SMN2KDM4EHTTTSHRHSD17B10 | |
| SCHEMBL16019318 | 0.96 | SMN1; SMN2 (0.93) | SMN1; SMN2KDM4EHTTTSHRHSD17B10 | |
| SCHEMBL23782803 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EHTTTSHRHSD17B10 | |
| SCHEMBL15116256 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EHTTTSHRHSD17B10 | |
| SCHEMBL29741196 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EHTTTSHRHSD17B10 | |
| SCHEMBL6122260 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EHTTTSHRHSD17B10 | |
| SCHEMBL4107462 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EHTTTSHRHSD17B10 | |
| SCHEMBL30711985 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM4EHTTTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12508268-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2025-12-30 | — | — | US | disclosed |
| US-20240285641-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| CN-117618423-A | Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy | 奥克兰联合服务有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117599049-A | Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy | 奥克兰联合服务有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-28 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| WO-2022155419-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022121805-A1 | FUSED RING COMPOUND AS NAV1.8 INHIBITOR AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-114591293-A | Fused ring compound as Nav1.8 inhibitor and application thereof | 成都康弘药业集团股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012156284-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012126791-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| EP-1848430-A2 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | Reddy US Therapeutics, Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
| WO-2006073973-A2 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | REDDY US THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, TDO2, IDO2 | SMN1; SMN2 3658/4885KDM4E 768/4885HTT 3100/4885 |
| US-20240285641-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | IDO1, TDO2, IDO2 | SMN1; SMN2 3658/4885KDM4E 768/4885HTT 3100/4885 |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | SMN1; SMN2 476/4885KDM4E 1401/4885HTT 293/4885 |
| US-12508268-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, IDO2, TDO2 | SMN1; SMN2 3177/4885KDM4E 1473/4885HTT 2237/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | SMN1; SMN2 3792/4885KDM4E 1691/4885HTT 1081/4885 |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | CETP, NPC1, LIPC | SMN1; SMN2 3687/4885KDM4E 1107/4885HTT 739/4885 |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | SMN1; SMN2 839/4885KDM4E 3764/4885HTT 2235/4885 |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | SMN1; SMN2 967/4885KDM4E 1732/4885HTT 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.